<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1147">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146219</url>
  </required_header>
  <id_info>
    <org_study_id>TYKM1601201</org_study_id>
    <nct_id>NCT05146219</nct_id>
  </id_info>
  <brief_title>Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation</brief_title>
  <official_title>A Phase II, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain or Leptomeningeal Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TYK Medicines, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TYK Medicines, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of TY-9591 tablets in the treatment of EGFR&#xD;
      mutation-positive non-small cell lung cancer (NSCLC) patients with brain or leptomeningeal&#xD;
      metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multi-center phase II study to evaluate the efficacy and safety in&#xD;
      EGFR mutated NSCLC patients with brain or leptomeningeal metastases. The patients will be&#xD;
      assigned to the appropriate treatment cohorts based on the criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intracranial Overall Response Rate (iORR)</measure>
    <time_frame>13 months.</time_frame>
    <description>iORR is defined as the proportion of patients with a best intracranial response of complete response (CR) or partial response (PR) during the study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extracranial Overall Response Rate (eORR)</measure>
    <time_frame>13 months.</time_frame>
    <description>eORR is defined as the proportion of patients with a best extracranial response of complete response (CR) or partial response (PR) during the study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>13 months.</time_frame>
    <description>ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) during the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>13 months.</time_frame>
    <description>DCR is defined as the proportion of patients with a best overall response of complete response (CR) , partial response (PR) or Stable disease (SD) ≥6 weeks during the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>13 months.</time_frame>
    <description>DoR is defined as the time from the date of first documented response (PR or CR) until the date of first documented disease progression or death due to any cause during the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival (PFS)</measure>
    <time_frame>13 months.</time_frame>
    <description>PFS is defined as time from date of first dose of study treatment until the date of first documented disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial Median Progression Free Survival (iPFS)</measure>
    <time_frame>13 months.</time_frame>
    <description>iPFS is defined as time from date of first dose of study treatment until the date of first documented intracranial disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the date of first dose until the date of death from any cause or loss to follow-up, whichever comes first, assessed up to 100 months</time_frame>
    <description>OS is defined as the time from the date of first dose of study treatment until death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>NSCLC</condition>
  <condition>EGFR Activating Mutation</condition>
  <condition>Brain Metastases</condition>
  <condition>Leptomeningeal Metastasis</condition>
  <arm_group>
    <arm_group_label>TY-9591 Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TY-9591 Tablets 160mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TY-9591 Tablets</intervention_name>
    <description>TY-9591 Tablets 160mg/d</description>
    <arm_group_label>TY-9591 Tablets</arm_group_label>
    <other_name>TY-9591</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with non-small cell lung cancer (NSCLC) by histology or cytology,&#xD;
             and with brain and leptomeningeal metastases. For LM patients, the diagnosis of&#xD;
             leptomeningeal metastasis requires detection of cancer cell or EGFR mutation in the&#xD;
             CSF.&#xD;
&#xD;
          2. Presence of an activating EGFR-sensitive mutations (including exon 19 deletions,&#xD;
             L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated&#xD;
             sites). A positive T790M mutation is required for patients who have progressed&#xD;
             following prior 1/2 generation EGFR-TKI therapy.&#xD;
&#xD;
          3. Stable brain/leptomeningeal metastases that do not require immediate or planned local&#xD;
             treatment for it during the study period.&#xD;
&#xD;
          4. Presence of intracranial and extracranial measurable lesions without local treatment&#xD;
             at the same time.&#xD;
&#xD;
          5. The ECOG score is 0-2 (including 0 and 2), and there is no deterioration 2 weeks&#xD;
             before the study, and the expected survival is not less than 3 months.&#xD;
&#xD;
          6. Adequate bone marrow reserve or organ function as demonstrated by any of the following&#xD;
             laboratory values:&#xD;
&#xD;
               1. Absolute neutrophil count ≥1.5×109/L and white blood cell count ≥3×109/L;&#xD;
&#xD;
               2. Platelet count ≥100×109/L;&#xD;
&#xD;
               3. Hemoglobin ≥90g/L;&#xD;
&#xD;
               4. Serum creatinine ≤1.5× upper normal limit (ULN) and creatinine clearance ≥50&#xD;
                  mL/min (calculated according to the Cockcroft and Gault formula);&#xD;
&#xD;
               5. AST and ALT≤2.5×ULN if no confirmed liver metastasis; AST, ALT≤5×ULN if confirmed&#xD;
                  liver metastasis;&#xD;
&#xD;
               6. Total bilirubin ≤1.5×ULN in the absence of proven liver metastasis; total&#xD;
                  bilirubin ≤3×ULN in patients with proven liver metastasis or Gilbert syndrome&#xD;
                  (hyperindirect bilirubinemia);&#xD;
&#xD;
               7. International standardized ratio (INR) ≤1.5, and activated partial prothrombin&#xD;
                  time (APTT) ≤1.5×ULN.&#xD;
&#xD;
          7. Male patients and female patients of reproductive age should take adequate&#xD;
             contraceptive measures from signing informed consent to 3 months after the last study&#xD;
             drug treatment; Women of childbearing age have negative pregnancy test results within&#xD;
             7 days of the first dose.&#xD;
&#xD;
          8. Patients having recovered from all grade ≤ 1 toxicities related to previous anticancer&#xD;
             therapies (CTCAE v 5.0) except for alopecia, platinum-therapy-related neuropathy&#xD;
             (where ≤2 is allowed) before first dose of study treatment.&#xD;
&#xD;
          9. Patients can understand and voluntarily sign the informed consent form.&#xD;
&#xD;
         10. Patient able to comply with study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any of the following treatment:&#xD;
&#xD;
               1. Previous treatment with 3rd generation EGFR inhibitor (Osimertinib, Almonertinib,&#xD;
                  Furmonertinib, etc.)；&#xD;
&#xD;
               2. The time from the treatment of reversible EGFR-TKI (e.g., Gefitinib, Erlotinib,&#xD;
                  Icotinib) to the first administration of the drug in this study did not exceed 8&#xD;
                  days or 5 half-lives (whichever is longer); the time from the treatment of&#xD;
                  irreversible EGFR-tkis (e.g., Afatinib, Dacomitinib, Neratinib, etc.) do not&#xD;
                  exceed 14 days or 5 half-lives (whichever is longer)；&#xD;
&#xD;
               3. Previous treatment with Systematic antitumor therapy, including standard&#xD;
                  chemotherapy, biotherapy and immunodrug therapy within 28 days before the first&#xD;
                  dose of the study drug, and traditional Chinese medicine antitumor therapy within&#xD;
                  7 days before the first dose of the study drug.&#xD;
&#xD;
               4. Receiving radiation to more than 30% of the bone marrow or with a wide field of&#xD;
                  radiation that had to be completed within 28 days of the first dose of study&#xD;
                  treatment; Radiotherapy with a limited field of radiation within 7 days of the&#xD;
                  first dose of study treatment or palliative radiation therapy for bone&#xD;
                  metastasis;&#xD;
&#xD;
               5. Previous treatment with whole brain radiotherapy (WBRT). Patients who have&#xD;
                  previously received stereotactic radiotherapy (SRT) or other CNS local treatments&#xD;
                  (such as intrathecal chemotherapy) can be enrolled if the time from the&#xD;
                  completion of treatment to the initial study medication is more than 2 weeks;&#xD;
&#xD;
               6. Uncontrollable pleural and abdominal effusion. For patients with pleural&#xD;
                  effusion, pleural effusion should be stabilized for 2 weeks prior to initial&#xD;
                  medication (diuretics, pleural effusion or pleural infusion are not allowed&#xD;
                  during this period);&#xD;
&#xD;
               7. Major surgery within 4 weeks of the first dose of study treatment;&#xD;
&#xD;
               8. Patients currently receiving (or at least within 14 days prior to receiving the&#xD;
                  first dose )medications or herbal supplements known to be potent inhibitors or&#xD;
                  inducers of cytochrome P450 isoenzyme (CYP)3A4.&#xD;
&#xD;
               9. Patients who are receiving and need to continue receiving medications during the&#xD;
                  study that are known to prolong the QTc interval or may cause tachycardia;&#xD;
&#xD;
              10. Participants in other clinical trials (other than non-interventional clinical&#xD;
                  trials) within 28 days prior to the first administration of the investigational&#xD;
                  drug.&#xD;
&#xD;
          2. Patients with leptomeningeal metastases (LM) who cannot be examined with enhanced MRI.&#xD;
             Presence of leptomeningeal metastases only.&#xD;
&#xD;
          3. Patients with CNS complications requiring emergency neurosurgical treatment (e.g.&#xD;
             surgery, etc.). Patients with CNS symptoms should be controlled by glucocorticoids&#xD;
             with an equivalent dose of more than 5mg dexamethasone 5 days prior to initial&#xD;
             administration.&#xD;
&#xD;
          4. Patients have spinal cord compression caused by tumor.&#xD;
&#xD;
          5. Clinically severe gastrointestinal dysfunction may affect the ingestion, transport or&#xD;
             absorption of the study drugs.&#xD;
&#xD;
          6. Cardiac function and disease are consistent with the following:&#xD;
&#xD;
               1. Corrected QT interval(QTc)&gt; 470 milliseconds from 3 electrocardiograms (ECGs);&#xD;
&#xD;
               2. Any clinically important abnormalities in rhythm;&#xD;
&#xD;
               3. Any factors that increase the risk of QTc prolongation;&#xD;
&#xD;
               4. Left ventricular ejection fraction (LVEF) &lt;50%.&#xD;
&#xD;
          7. Active human immunodeficiency virus (HIV), syphilis, hepatitis c virus (HCV) or&#xD;
             hepatitis b virus (HBV) infection, with the exception of asymptomatic chronic&#xD;
             hepatitis b or hepatitis c carriers.&#xD;
&#xD;
          8. Previous history of interstitial lung disease(ILD)#drug-induced ILD or radiation&#xD;
             pneumonitis require steroid treatment, or any evidence of clinically active ILD&#xD;
             diseases.&#xD;
&#xD;
          9. Previous allogeneic bone marrow transplant.&#xD;
&#xD;
         10. Pregnant or lactating women.&#xD;
&#xD;
         11. Any other disease or medical condition that is unstable or may affect the safety or&#xD;
             study compliance.&#xD;
&#xD;
         12. Hypersensitivity to TY-9591 or similar compounds or excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute/Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuankai Shi, MD</last_name>
    <phone>+86-10-87788293</phone>
    <email>syuankaipum@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuankai Shi, MD</last_name>
      <phone>+86-10-87788293</phone>
      <email>syuankaipum@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

